Praćenje promjena koncentracije topljivoga receptora za TGF beta III specifičnoga biomarkera u plazmi bolesnica s karcinomom dojke

doctoral thesis

• Title (english): Monitoring of plasma concentration changes of specific biomarker TGF beta III soluble receptor in breast cancer patients
• Author: Darko Jurišić
• Mentor: Lovorka Grgurević (mentor)
• Committee member: nije dostupno (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; Zagreb
• Defense date and country: 2016-05-10, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences
• Universal decimal classification (UDC): 61 - Medical sciences

Abstract

Uvod i cilj istraživanja
Karcinom dojke najčešće je maligno oboljenje žena od kojeg obolijeva četvrtina
novooboljelih ženskih osoba u svijetu i Hrvatskoj. Cilj ove studije bio je istražiti
povezanost molekule TGF β rIII u uzorcima plazme bolesnica s karcinomom dojke i
tkiva tumora s prognozom bolesti.
Ispitanici i metode
U istraživanju su bile uključene 62 bolesnice sa zloćudnim tumorom dojke i 36
zdravih ispitanica u kontrolnoj skupini. ELISA metodom određivali smo koncentraciju
TGF β rIII u plazmi bolesnica prije i nakon operativnog zahvata, a imunohistokemijski
izražajnost TGFβ rIII proteina u uzorcima tumora dojke.
Rezultati
U ovom istraživanju po prvi puta smo izmjerili vrijednosti TGF β rIII u plazmi
bolesnica s karcinomom dojke te u plazmi zdravih ispitanica. Prosječna koncentracija
TGF β rIII u plazmi bolesnica s karcinomom dojke iznosila je 7,63 ng/ml (raspon
14,41 ng/ml), što je bilo značajno niže u odnosu na kontrolnu skupinu (p<0,001).
Bolesnice s preoperativno izmjerenom koncentracijom TGF β rIII u plazmi nižom od
7,83 ng/ml imale su statistički značajno manji udio preživjelih bez nepovoljnog
primarnog ishoda (metastaza, lokalni recidiv ili pojava novog primarnog tumora) u
usporedbi s ostalim bolesnicama (p=0,045). Bolesnice koje su imale loše
prognostičke parametre (LN+, ER/PR-, Her2+), a čija je koncentracija TGF β rIII u
plazmi prije operativnog zahvata bila veća od 7,83 ng/ml, imale su značajno bolje
preživljenje bez nepovoljnog primarnog ishoda u odnosu na bolesnice s tumorima
istih karakteristika ali nižom koncentracijom TGF β rIII u plazmi (p=0,016).
Zaključak
U ovom istraživanju pokazali smo da bi se TGF β rIII u plazmi bolesnica s
karcinomom dojke mogao koristiti kao novi prediktor ishoda u skupini bolesnica s
niskim rizikom bolesti te je zanimljiv predmet budućih istraživanja.

Abstract (english)

Background and aim
Breast cancer is the most common female cancer disease of which are affected one
quarter of women treated for cancer in the world and Croatia. The aim of this study
was to explore the relationship of the molecule TGF β rIII in samples of plasma of the
patients with breast cancer and tumour tissue with prognosis of the disease.
Subjects and Methods
The study included 62 female patients with breast cancer and 36 respondents in the
control group. ELISA method was used to determine the concentration of the TGF β
rIII in the patients' plasma before and after the surgery, while immunohistochemical
analysis was used for expression of TGF β rIII protein in breast tumor samples.
Results
In this research for the first time we measured the values of the TGF β rIII in plasma
of the patients with breast cancer and in plasma of healthy respondents. The average
concentration of the TGF β rIII in plasma of the patients with breast cancer was 7,63
ng/ml (range 14,41 ng/ml), which was significantly lower concentration compared to
the control group (p<0,001). Patients with breast cancer with preoperative
concentration of the TGF β rIII in plasma lower than 7,83 ng/ml had statistically
significantly lower survival rate without adversely primary outcome (metastasis, local
recurrence or appearance of new primary tumors) compared to other patients
(p=0,045). Patients with poor prognostic parameters (LN+, ER/PR-, Her2+) and with
preoperative concentration of the TGF β rIII in plasma higher than 7,83 ng/ml had
statistically significantly better survival rate without adversely primary outcome
compared to patients with lower concentration of the TGF β rIII in plasma (p=0,016).
Conclusion
This study demonstrated that TGF β rIII in the plasma of patients with breast cancer
disease could be a new predictor of outcome in a group of patients with low-risk
disease and is an interesting subject for future research.

• Keywords: medicina
• Keywords (english): medicine
• Language: croatian
• URN:NBN: urn:nbn:hr:105:581801
• Study programme: Title: Biomedicine and Health Sciences; Study programme type: university; Study level: postgraduate; Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstva (doktor/doktorica znanosti, područje biomedicine i zdravstva)
• Type of resource: Text
• Extent: 130 str.
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-05-05 08:06:01